Edition:
United Kingdom

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

8.25USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
513,978
52-wk High
$25.11
52-wk Low
$5.91

Latest Key Developments (Source: Significant Developments)

Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Merck & Co Inc ::NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014.NEWLINK GENETICS-UNDER MERCK AMENDMENT, MODIFIED MERCK'S SUBLICENSE OF IP RIGHTS UNDER PHAC LICENSE AGREEMENT TO BE NON-EXCLUSIVE ON EBOLA SUDAN FIELD OF USE.NEWLINK GENETICS - AMENDMENT ALSO ADJUSTS EXPIRATION OF MERCK'S OBLIGATION TO PAY ROYALTIES TO BPS BASED ON ROYALTY TERM OF PHAC LICENSE AGREEMENT.  Full Article

NewLink Genetics reports Q3 loss per share $0.69
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - NewLink Genetics Corp :Q3 loss per share $0.69.NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​.NewLink Genetics Corp - Qtrly ‍total operating revenues $5.5 million versus $15.3 million.Q3 earnings per share view $-0.74, revenue view $3.4 million -- Thomson Reuters I/B/E/S.  Full Article

Newlink genetics announces FDA orphan-drug designation for Indoximod
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Newlink Genetics Corp :Newlink Genetics announces FDA orphan-drug designation for Indoximod.‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​.  Full Article

NewLink Genetics Q3 loss $0.54/shr
Tuesday, 1 Nov 2016 

Newlink Genetics Corp : NewLink Genetics Corp says expects to have approximately $132 million in cash and equivalents on December 31, 2016 . NewLink Genetics Corp - qtrly loss per share $0.54 . Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S .Press release - NewLink Genetics Corp provides operational update and reports third quarter 2016 financial results.  Full Article

Newlink Genetics Q2 loss per share $1.12
Friday, 29 Jul 2016 

Newlink Genetics Corp : Q2 loss per share $1.12 . Implemented a significant restructuring program following may results of impress phase 3 study of algenpantucel-l . Reducing headcount from approximately 230 to approximately 130 . Recorded $12.3 million in restructuring expenses in q2 . Winding down hyperacute cellular immunotherapy clinical trials that do not include a checkpoint inhibitor combination .In q3, company expects to record small additional charges relating to closing or reduction of leased facilities.  Full Article

Newlink Genetics elected to terminate Wuxi agreement
Monday, 6 Jun 2016 

Newlink Genetics Corp: Elected to terminate Wuxi agreement . Determined to discontinue manufacturing operations for Algenpantucel-L and to terminate Wuxi agreement .Expects to make certain payments under outstanding work orders in connection with termination.  Full Article

Newlink Genetics announces results from phase 3 impress trial of Algenpantucel-L
Monday, 9 May 2016 

Newlink Genetics : Impress phase 3 study of Algenpantucel-l for patients with resected pancreatic cancer did not achieve its primary endpoint . L for patients with resected pancreatic cancer did not achieve its primary endpoint . Overall survival from time of randomization was 29.3 months for both groups combined . There was also no statistical difference for long-term survival. . Newlink genetics corp says there was no statistically significant difference between two groups . "in light of these negative results, our scientific and clinical teams will focus on other promising opportunities in our pipeline" . Newlink genetics corp says reiterates that its goal and expectation is to finish 2016 with two years of cash on hand .L for patients with resected pancreatic cancer.  Full Article

NewLink Genetics Corp presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer
Friday, 22 Jan 2016 

NewLink Genetics Corp:Announces the presentation of data that describe a combination therapy of indoximod, an IDO pathway inhibitor, plus gemcitabine/nab-paclitaxel, for patients with metastatic pancreatic cancer.Combination immunotherapeutic approach was well tolerated and shows encouraging durable responses with a delayed pattern.  Full Article

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014